Edity Therapeutics Is A Biotechnology Company Based In Rehovotisraelfounded In 2020The Company Focuses On Developing Innovative Therapeutic Platforms That Utilize The Immune System To Deliver Therapeutic Proteins Directly Into The Cytoplasm Of Diseased Cellsthis Method Aims To Enhance Patient Health By Targeting Challenging Disease Pathways That Traditional Therapies Often Struggle To Reach The Primary Service Of Edity Therapeutics Involves Harnessing Immune Cellssuch As T Cells And Nk Cellsto Deliver Therapeutic Proteins To Specific Target Cellsthis Technology Addresses Limitations Of Existing Therapies Related To Tissue Tropismtoxicityand Payload Sizethe Company Is Developing A Unique Immune Cell Delivery Platform That Allows For Precise Targeting Of Diseased Cellsparticularly In The Areas Of Cancer And Genetic Diseasescurrentlyedity Therapeutics Is In The Pre Clinical Stage And Is Categorized As Pre Seed In Fundingindicating Its Early Development Phase And Potential For Future Growth
